Background: Neurotoxicity is a recognized complication of cyclosporine A (CSA) treatment. The incidence of severe CSA-related neurological complications following hematopoietic stem cell transplantation (HSCT) is 4-11%. Methods: We describe 6 cases of CSA related neurotoxicity out of 67 matched related HSCT performed in paediatric Middle East patients affected by haemoglobinopaties (5 beta thalassemia major, 1 sickle cell disease-SCD). Conditioning regimen consisted of iv busulphan, cyclophosphamide and graft-versus-host-disease (GvHD) prophylaxis with CSA, methylprednisolone, methotrexate and ATG.
Background
Cyclosporin A (CSA) is a calcineurin inhibitor routinely used as graft-versus-host-disease (GvHD) prophylaxis after haematopoietic stem cell transplantation (HSCT). Common CSA related side-effects include renal dysfunction, arterial hypertension, hepatic toxicity, gingival hyperplasia, hypertrichosis, opportunistic infections and tremors [1] . Severe neurotoxicity such as confusion, disorientation, decreased responsiveness, visual hallucinations, delusions, seizures, pyramidal motor weakness, cortical blindness, aphasia and ataxia is reported in 4% to 11% patients undergoing HSCT [2] [3] [4] [5] [6] . Unfortunately neurotoxicity can occur both at therapeutic and at high CSA levels [2, 3] . The reported incidence of CSA neurotoxicity post HSCT may be underestimated because the clinical picture could be confused with other neurological complications such as infections, metabolic disturbances (hypomagnesaemia, hypocolesterolaemia, hypo/ hypernatraemia, hypercalcaemia), toxic encephalopathy (drug induced by intratecal or systemic chemotherapeutic agents, oppioids, amphotericin B or radiotherapy), thrombotic microagiopathy, vascular events and structural neurological lesions [4] . Many risk factors for the development of CSA-related neurotoxicity have been investigated, including the use of methylprednisolone, arterial hypertension, fluid overload, hypocholesterolaemia, hypomagnesaemia and pre-existing brain disease [5, 7] . The brain magnetic resonance imaging (MRI) finding usually associated to CSA neurotoxicity is known as posterior reversible leukoencephalopathy syndrome (PRES), typically distributed in the posterior regions of the white matter of the brain [5] [6] [7] [8] . In general the prognosis of CSA neurotoxicity is good [4] and posterior leukoencephalopathy usually resolves completely with dose reduction or drug withdrawal. However, some cases of non-reversible encephalopathy syndrome have been described with occurrence of late epilepsy and late persistent electroencephalogram (EEG) abnormalities [9, 10] .
We report 6 cases of CSA related neurotoxicity occurring among 67 children undergoing HSCT for haemoglobinopaties and discuss early diagnosis and management. 
Methods

Patients' characteristics
CSA administration and monitoring
GvHD prophylaxis consisted of CSA, short course of iv Methotrexate (MTX) 10 mg/m2 on d 1, 3 and 6 and metilprednisolone 0.5 mg/kg from d -1 until d 25. ATG was added in 3 patients.
CSA was used orally at the dose of 10 mg/kg/day from day -2. The dose was adjusted to a trough plasma level of 150-250 ng/mL with twice weekly monitoring. In the absence of GvHD, CSA was tapered from d 60 until discontinuation at 1 year.
Monitoring for CSA related side effects consisted of daily examination, 6 hourly blood pressure and daily blood routine biochemistry including magnesium till day 30, followed by 3 times weekly till day 60. Arterial hypertension above 75°percentile for age and weight was treated with oral calcium antagonists. Fluid overload was treated with iv furosemide. Magnesium was supplemented for plasma levels below 0.8 mmol/Lt. Children developing CSA neurotoxicity underwent neuro-radiological (MRI scan) and electrophysiological studies (EEG). In case of epileptic signs, EEG was repeated after 24 hours and then on regular basis in order to monitor the outcome of the anticonvulsive therapy. CSA-related toxicity was evaluated using the National Cancer Institute common toxicity criteria (NCI/CTC). Clinical management was lead by the HSCT specialists on the HSCT ward with the collaboration of intensivists, neurologists, neurophysiologists and neuroradiologists.
Results
Clinical course
All six patients developing neurotoxicity presented prodromes 1-2 days before overt neurotoxicity. Prodromes were arterial hypertension (n = 5), headache (n = 2), visual disturbances (n = 1) or vomiting (n = 1). Symptoms of CSA neurological toxicity were characterized by: generalized seizures (grade 3-4 neurotoxicity) (n = 4), endocranial hypertension evidenced by impaired level of consciousness (grade 3 confusion) associated to bradycardia, arterial hypertension and cerebral vomiting (n = 1), and blurred vision (grade 3 visual toxicity) (n = 1). The median day of appearance was 11 days after HSCT (range +1 to +40). When neurological symptoms appeared, CSA plasma levels were in range in all patients (median 178, range 69-250 ng/ml). Clinical and laboratory findings are summarized in Table 3 . None of the patients had evidence of thrombotic microangiopathy. None of the clinical pictures were suggestive for viral encephalitis, as evidenced by apyrexia, normal CRP, negative molecular virological screening on plasma, non suggestive MRI and EEG pictures.
Neuroradiological and electrophysiological findings
Neuroradiological and electrophysiological studies were performed within 24 hours from neurological symptoms appearance. A CT scan performed in patient #5 because MRI was not immediately available showed a minimal subdural haemorrhagic layer compatible with post epileptic trauma. MRI was performed in all patients. In 5/6 patients, MRI showed a symmetric involvement of the posterior portions of the cerebral hemispheres, while one case showed abnormal signals hyperintense in T2 and Flair images in the cerebellar hemispheres, involving predominantly the white matter but also the cortex (figure 1, 2). In 5 out of the 6 patients studied, a moderate gyral swelling was present. On diffusion weighted images these lesions had an increase diffusion (hyperintens sygnal on apparent diffusion coefficient maps) consistent with vasogenic oedema.
In five out of 6 children, it was possible to perform an EEG at the time of the neurological symptoms onset. EEG of three out of five patients showed a status epilepticus ( Figure 3, 4, 5) . The other two patients showed, respectively, a focal delta activity and focal epileptiform discharges. EEGs were repeated every 2-3 days in the acute phase in order to adjust the anticonvulsive therapy.
Treatment
On occurrence of neurotoxicity, CSA was immediately withdrawn. After 2 days of calcineurin-inhibitor washout, tacrolimus alone (n = 3) or tacrolimus and mycophenolate mofetile (n = 3) (according to the individual GvHD risk) were introduced with tacrolimus level monitoring. Neurological symptoms resolved within 2-3 days following CSA withdrawal and did not re-occur during tacrolimus treatment. Intravenous lorazepam was immediately administered at seizures unset, followed by anticonvulsive treatment with phenitoyn. Patient #1 (SCD) required association with phenobarbital to control generalized seizures (table 3) . Intravenous mannitol was used successfully in patient #2 and #6 to treat confusion, vomiting, headache and blurred vision related to endocranial hypertension. Anticonvulsive therapy was tapered and stopped after normalization of EEG findings. In patient #6 phenitoyn was withdrawn after 3 weeks of treatment because of the onset of a severe hepatic-toxicity (elevation of liver enzymes and bilirubin) in the presence of a liver biopsy suggestive of drug-related injury. Liver function normalized following phenitoyn Outcome Neuroradiological monitoring was performed by MRI every 7-14 days until complete remission of the diffuse signal alterations, which occurred after a median of 15 days (range 12-90 days) from CSA withdrawal. Non epileptiform EEG abnormalities were still detectable in all patients in the 15 days after the onset of symptoms. The complete normalization of EEG occurred after a median of 120 days (range 60-140 days). Five patients are alive and symptoms-free at a median follow up of 1005 days (range 320-1065) without neurological sequelae, while one patient died on day 60 for grade IV GvHD, without neurological symptoms.
Discussion
CSA neurotoxicity is a well recognized complication observed after HSCT. Incidence of neurotoxicity in patients receiving allogeneic HSCT varies according to the underlying disease [6] . In the paediatric age incidence in haematological malignancies ranges between 4% and 11% [3, 12] . The incidence is higher in non malignant disorders, although very few data have been published. In patients affected by haemoglobinopaties, a single published series suggests a very high incidence of CSA related neurotoxicity (28.8%) [7] . We describe a large and homogenous series of children with haemoglobinopaties who experienced a 9% incidence of CSA neurotoxicity following HSCT. Our data confirm previous findings on increased risk of CSA related severe neurotoxicity in patients with non malignancies, but suggests that, up to date, early diagnosis and intervention may ameliorate the incidence and severity. Patients with hemoglobinopaties may be at increased risk of neutoxicity due to impaired liver function secondary to iron overload as consequence of irregular iron chelation and blood-born viral infection. Both risk factors were heavily present in our series and the series reported by Erer et al [7] . CSA is metabolized in the liver as the drug is converted by the iso-enzymes of hepatic cytochrome P450. Impaired hepatic function may thus affect CSA metabolism triggering neurotoxicity. Another factor which may have influenced the onset of seizures is the use of iv busulfan in the preparative regimen. It has been reported that busulfan may induce seizures at the time of administration, and this may play a role in the subsequent appearance of neurotoxicity due to CSA. However, our policy of therapeutic dose adjustment and seizure prophylaxis during administration did not result in any immediate neurological toxicity.
Moreover, our results suggest that early patients' monitoring by neuro-radiological and electrophysiological studies and improved awareness of prodromes can reduce the incidence and long-term consequences of these events. Among the prodromes, arterial hypertension was the most premature and should therefore routinely evaluated and promptly intervened on. In our series, prompt discontinuation of CSA resulted in good prognosis with no neurological sequels. As alternative GvHD prophylaxis, we opted for tacrolimus. This calcineurin inhibitor, although similar to CSA in mechanism and metabolism, did not produce neurological side effects in this series.
Conclusions
Our results confirm the high incidence of CSA related neurotoxicity in patients with non malignant disorders undergoing HSCT. This could be explained by their impaired organ functions due to the underlying disease or need for higher CSA doses. The awareness of prodromes of CSA related neurotoxicity (arterial hypertension, headache and visual disturbances) and early recognition with electrophysiological and imaging strategies is very important for prompt intervention on these patients, in order to reduce the risk of CSA related neurological events, in particular irreversible sequels. Our experience confirms that the gold standard approach to evaluate CSA related brain lesions is MRI, highly sensitive to detect the posterior diffuse alterations consistent with vasogenic oedema typical for PRES, and that CSA withdrawal should be prompt to prevent irreversible sequels.
Abbreviations CSA: cyclosporine A; HSCT: haematopoietic stem cell transplantation; PRES: posterior reversible encephalopathy syndrome; CNS: central nervous system; MRI: magnetic resonance imaging; EEG: electroencephalography; GvHD: graft versus host disease; SCD: sickle cell disease; B-thal: beta thalassemia.
